Records containing: Melanoma

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2026-04-27
  A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
• CLINICAL_TRIALS study record update · 2026-04-27
  A Multicentre Randomised Open-label Phase III Study of Stereotactic Radiosurgery, in Addition to Standard Systemic Therapy for Patients With Metastatic Melanoma or Newly Diagnosed Metastatic NSCLC and Asymptomatic or Oligo-symptomatic Brain Metastases
• CLINICAL_TRIALS study record update · 2026-04-24
  A Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
• CLINICAL_TRIALS study record update · 2026-04-24
  Assessment of Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Cytochrome P450 Substrates: Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
• CLINICAL_TRIALS study record update · 2026-04-24
  Clinical Genetics Branch (CGB) Eligibility Screening Survey
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2026-04-24
  An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients With Advanced Solid Tumors.
• CLINICAL_TRIALS study record update · 2026-04-24
  Evaluation for NCI Surgery Branch Clinical Research Protocols
• CLINICAL_TRIALS study record update · 2026-04-24
  Natural History Study of Early Life Exposures in Agriculture (ELEA)
• CLINICAL_TRIALS study record update · 2026-04-24
  A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies
• CLINICAL_TRIALS study record update · 2026-04-24
  The Value of Circulating Tumour DNA in Early Detection of Recurrence of Melanoma
• CLINICAL_TRIALS study record update · 2026-04-23
  A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics of GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU Authorized Keytruda® in Participants With Stage II and III Melanoma Requiring Adjuvant Treatment With Pembrolizumab
• CLINICAL_TRIALS study record update · 2026-04-23
  A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS
• CLINICAL_TRIALS study record update · 2026-04-23
  A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS
• CLINICAL_TRIALS study record update · 2026-04-23
  A Prospective Registry Study of a Primary Melanoma Gene-signature to Predict Sentinel Node (SN) Status and Determine Its Prognostic Value for More Accurate Staging of SN-negative Melanoma Patients.
• CLINICAL_TRIALS study record update · 2026-04-23
  Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma
• CLINICAL_TRIALS study record update · 2026-04-23
  A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors
• CLINICAL_TRIALS study record update · 2026-04-22
  A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
• CLINICAL_TRIALS study record update · 2026-04-21
  A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
• CLINICAL_TRIALS study record update · 2026-04-20
  Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
• CLINICAL_TRIALS study record update · 2026-04-20
  An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in Patients With Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer or Melanoma Who Are Treated With Ezabenlimab
• CLINICAL_TRIALS study record update · 2026-04-20
  Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
• CLINICAL_TRIALS study record update · 2026-04-20
  A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
• CLINICAL_TRIALS study record update · 2026-04-17
  A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
• CLINICAL_TRIALS study record update · 2026-04-16
  Phase IIa Study of HX009+IN10018 in Patients With Advanced Solid Tumours, Including Biliary Tract Malignancies and Malignant Melanoma, Treated With or Without Standard Chemotherapy
• CLINICAL_TRIALS study record update · 2026-04-16
  Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)